Year: 2002 Source: Insight on the News, (15 October 2002), 2p. SIEC No: 20050268

This article draws attention to a study by A Khan regarding the approval of selective serotonin reuptake inhibitor (SSRI) antidepressants by the U.S. Food & Drug Administration (FDA) in spite of evidence for an increased risk of suicide among patients treated with SSRIs. Inconsistencies in the findings of FDA drug-trials for SSRIs are highlighted, & remaining gaps in the data are identified. Implications for research, policy, & practice are also discussed.